| __timestamp | Exelixis, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 72429000 |
| Thursday, January 1, 2015 | 57305000 | 78634000 |
| Friday, January 1, 2016 | 116145000 | 75374000 |
| Sunday, January 1, 2017 | 159362000 | 92157000 |
| Monday, January 1, 2018 | 206366000 | 93326000 |
| Tuesday, January 1, 2019 | 228244000 | 103132000 |
| Wednesday, January 1, 2020 | 293355000 | 110171000 |
| Friday, January 1, 2021 | 401715000 | 218817000 |
| Saturday, January 1, 2022 | 459856000 | 233827000 |
| Sunday, January 1, 2023 | 542705000 | 267194000 |
| Monday, January 1, 2024 | 492128000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology and pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Exelixis, Inc. and Lantheus Holdings, Inc. have shown distinct strategies in handling these costs. From 2014 to 2023, Exelixis, Inc. saw a staggering 967% increase in SG&A expenses, reflecting its aggressive expansion and investment in growth. In contrast, Lantheus Holdings, Inc. managed a more modest 269% rise, indicating a more conservative approach. By 2023, Exelixis's SG&A expenses were nearly double those of Lantheus, suggesting a potential trade-off between growth and cost efficiency. This data provides a fascinating insight into how two industry players navigate financial management, offering valuable lessons for investors and competitors alike.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Lantheus Holdings, Inc.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Genmab A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Comparing SG&A Expenses: Lantheus Holdings, Inc. vs Celldex Therapeutics, Inc. Trends and Insights